Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Participants must meet all of the following criteria to be included in this study:~* Chinese healthy adult volunteers (males and females)~* Non-smoking, male or female age ≥18 years and ≤45 years old at the time of obtaining written consent. To be considered non-smokers, participants must have discontinued smoking from screening before first dosing.~* Participants with a Body Mass Index ≥18.5 and \<24.5 kilograms per meters squared at screening~* Participants who undergo screening within 3 weeks before study treatment and are confirmed to be eligible by the investigator~Exclusion Criteria:~Participants who meet any of the following criteria will be excluded from this study:~* Participants who weigh less than 50 kilograms~* Females who are breastfeeding or pregnant at Screening or Baseline~* Females of childbearing potential~* Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks before first dosing~* Evidence of disease that may influence the outcome of the study within 4 weeks before first dosing~* Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of perampanel at Screening~* Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening~* A prolonged QT/corrected QT (QTc) interval (QTc interval for heart rate using Fredericia's formula \>450 milliseconds) as demonstrated by a repeated ECG at Screening or Baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Perampanel single-dose Part: 2 mg group (Type: EXPERIMENTAL): Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
- Perampanel single-dose Part: 4 mg group (Type: EXPERIMENTAL): Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
- Perampanel single-dose Part: 8 mg group (Type: EXPERIMENTAL): Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
- Perampanel multiple-dose Part (Type: EXPERIMENTAL): Participants will receive multiple oral dose of perampanel (2 milligrams per day \[mg/day\] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).